Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Pathological fracture

Palliative and end-of-life care · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Fracture with threatened limb or instability

A completed pathological fracture can cause severe pain, bleeding and neurovascular compromise. An open fracture, pulseless limb, compartment syndrome, unstable pelvis or associated spinal neurological signs requires emergency specialist management.

Action: Use ABCDE care, do not force alignment or weight bearing, support the limb, give titrated analgesia and document distal neurovascular status before and after any splint. Cover open wounds, assess blood loss and contact orthopaedic or tumour specialists immediately for imaging, reduction, fixation and haemorrhage planning.

Synopsis

Recognise fracture through diseased bone and lesions at imminent risk, protect the limb and neurovascular structures, image and biopsy in the correct sequence and coordinate fixation, radiotherapy, bone-targeted treatment, rehabilitation or comfort-focused care.

  • A pathological fracture occurs through bone weakened by metastasis, myeloma, primary tumour, osteoporosis or another metabolic lesion, sometimes after minimal or no trauma.
  • New focal weight-bearing pain, night pain, functional decline or pain despite analgesia can signal an impending fracture before displacement occurs.
  • Sudden pain, deformity, inability to use the limb, shortening or crepitus requires immediate immobilisation, neurovascular assessment, analgesia and orthopaedic review.
  • First-line imaging is two-view plain radiography including the entire affected bone and adjacent joints; image before forcing movement or weight bearing.
  • CT defines cortical destruction and fixation anatomy, while MRI best shows marrow and soft-tissue extension; staging imaging establishes whether disease is solitary or widespread.
  • A solitary destructive lesion without secure cancer diagnosis needs orthopaedic-oncology planning before biopsy, because an incorrectly placed tract can compromise definitive surgery.
  • Mirels scoring supports assessment of impending long-bone fracture, but progressive functional pain and specialist judgement matter more than a threshold used in isolation.
  • Prophylactic stabilisation of a high-risk lesion is generally safer and restores function more predictably than operating after a displaced fracture.
  • Fixation or endoprosthetic replacement is followed by oncology review and often radiotherapy; bisphosphonate or denosumab reduces future skeletal events but does not repair an acute break.
  • When surgery is unlikely to benefit, provide stable positioning, pressure care, rapid analgesic access, practical transfer planning and an honest discussion of expected mobility.

Key red flags

A pulseless, pale or cold limb or progressive motor and sensory loss indicates neurovascular compromise.

Pain out of proportion, tense swelling or pain on passive stretch suggests compartment syndrome.

An open wound over a fracture risks contamination and tumour or bone exposure and needs emergency care.

Pelvic fracture with hypotension, abdominal distension or falling haemoglobin may conceal life-threatening haemorrhage.

Back pain with weakness, sensory change or sphincter dysfunction moves immediately to the MSCC pathway.

A solitary aggressive lesion must not undergo unplanned biopsy or fixation before bone-tumour specialist review.

New weight-bearing pain in known metastasis can be an impending fracture even when the initial radiograph shows no complete break.

Threatened limb or compartment

Absent pulse, increasing tense swelling, pain on passive stretch, pallor or progressive sensory and motor loss requires immediate orthopaedic and vascular action.

Investigation priorities

01
First-line whole-bone radiographsFirst stepFirst line

Obtain orthogonal views of the entire affected bone including both adjacent joints without unsafe loading or manipulation.

Management branches

Completed fractureProtect, image and stabilise

Sudden pain, deformity or functional loss indicates a pathological fracture.

  1. Immobilise in a comfortable position, provide rapid analgesia, document neurovascular findings, assess blood loss and obtain whole-bone radiographs.
  2. Contact orthopaedics promptly and define cancer diagnosis, prognosis, comorbidity, previous radiotherapy and the functional outcome important to the patient.
  3. Use fixation or replacement designed for immediate function and expected lifetime, followed by oncology, radiotherapy and rehabilitation planning.

Key medicines

Pre-emptive opioid for fracture movementGive an immediate-release opioid dose before imaging, turns or transfers, selected from current opioid exposure and renal function; titrate the regular regimen from documented rescue use and prescribe bowel care.Monitor sedation, respiratory rate, delirium and myoclonus and avoid repeatedly moving an unstable limb simply because analgesia has reduced warning pain.
Denosumab for future skeletal-event reductionFor an eligible solid tumour with bone metastases, use the commissioned oncology regimen, commonly 120 mg subcutaneously every four weeks, with calcium and vitamin D management tailored to renal and calcium status.Check calcium, vitamin D, dental health and jaw symptoms; severe hypocalcaemia is more likely in kidney failure and jaw osteonecrosis risk rises with cumulative exposure.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • Long-bone metastasis management reviewAssessment, biopsy sequence, prophylactic fixation and multidisciplinary treatment of long-bone disease.
  • NICE NG234 spinal metastases and MSCCSpinal pain, stability, imaging, treatment and rehabilitation when pathological collapse affects the spine.
  • NICE TA265 denosumab for bone metastasesCommissioned use of denosumab to prevent skeletal-related events in eligible solid tumours.
  • RCR radiotherapy dose fractionationPalliative radiotherapy schedules for painful bone metastases and postoperative treatment.
  • NICE CG140 strong opioidsOpioid rescue, titration, adverse effects and communication in palliative pain.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom